Patents Assigned to FORTIS THERAPEUTICS, INC.
  • COMBINATION THERAPY WITH FOR46 FOR CANCER
    Publication number: 20240058464
    Abstract: Disclosed herein are methods of treating cancer. Some such methods include administration of a first anti-cancer agent that increases CD46 expression on the surface of a cancer cell. Some embodiments include administration of a second anti-cancer agent that binds CD46. The second anti-cancer agent may include an immunoconjugate comprising a CD46 binding domain and effector agent.
    Type: Application
    Filed: January 6, 2022
    Publication date: February 22, 2024
    Applicants: Fortis Therapeutics, Inc., The Regents of the University of California
    Inventors: Bin LIU, Andrew DORR, Jay LICHTER, Marc NASOFF, Leonard POST
  • Immunoconjugates targeting CD46 and methods of use thereof
    Patent number: 11484604
    Abstract: Disclosed herein are immunoconjugates comprising a CD46 binding domain and effector agent. Further provided herein are methods of treating cancer comprising administering to a subject having cancer a pharmaceutical composition comprising immunoconjugates comprising a CD46 binding domain and effector agent.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: November 1, 2022
    Assignee: FORTIS THERAPEUTICS, INC.
    Inventors: Marc Nasoff, Andrew Dorr